Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 9 |
| List of Tables | 6 | 3 |
| List of Figures | 9 | 3 |
| Autoimmune Disorders Therapeutics Market to 2017 - Introduction | 12 | 2 |
| GBI Research Report Guidance | 13 | 1 |
| Autoimmune Disorders Therapeutics Market to 2017 - Market Overview | 14 | 4 |
| Introduction | 14 | 1 |
| Revenue | 14 | 1 |
| Annual Cost of Treatment | 15 | 1 |
| Treatment Usage Pattern | 16 | 1 |
| Disease Population | 17 | 1 |
| Treatment Seeking Population | 17 | 1 |
| Diagnosed Population | 17 | 1 |
| Prescription Population | 17 | 1 |
| Autoimmune Disorders Therapeutics Market to 2017: Geographical Landscape | 18 | 14 |
| Revenue Analysis by Geography | 18 | 1 |
| The US | 19 | 1 |
| Revenue | 19 | 1 |
| Annual Cost of Treatment | 20 | 1 |
| Treatment Usage Patterns | 21 | 1 |
| Disease Population | 22 | 1 |
| Treatment Seeking Population | 22 | 1 |
| Diagnosis Population | 22 | 1 |
| Prescription Population | 22 | 1 |
| Top Five Countries of Europe | 23 | 1 |
| Revenue | 23 | 1 |
| Revenue by Country | 24 | 1 |
| Annual Cost of Treatment | 25 | 1 |
| Treatment Usage Patterns | 26 | 1 |
| Disease Population | 27 | 1 |
| Treatment Seeking Population | 27 | 1 |
| Diagnosis Population | 27 | 1 |
| Prescription Population | 27 | 1 |
| Japan | 28 | 1 |
| Revenue | 28 | 1 |
| Annual Cost of Treatment | 29 | 1 |
| Treatment Usage Patterns | 30 | 1 |
| Disease Population | 31 | 1 |
| Treatment Seeking Population | 31 | 1 |
| Diagnosis Population | 31 | 1 |
| Prescription Population | 31 | 1 |
| Autoimmune Disorders Therapeutics Market to 2017: Therapeutic Landscape | 32 | 48 |
| Rheumatoid Arthritis Therapeutics Market | 32 | 1 |
| Introduction | 32 | 1 |
| Revenue | 32 | 1 |
| Revenue by Country | 33 | 2 |
| Branded vs. Generics | 35 | 1 |
| Treatment Algorithm | 36 | 1 |
| Annual Cost of Treatment | 36 | 1 |
| Treatment Usage Pattern | 37 | 1 |
| Disease Population | 38 | 1 |
| Treatment Seeking Population | 38 | 1 |
| Diagnosis Population | 38 | 1 |
| Prescription Population | 38 | 1 |
| Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market | 39 | 1 |
| Drivers for the Rheumatoid Arthritis Therapeutics Market | 39 | 1 |
| Barriers for the Rheumatoid Arthritis Therapeutics Market | 40 | 1 |
| Multiple Sclerosis Therapeutics Market | 41 | 1 |
| Introduction | 41 | 1 |
| Revenue | 42 | 1 |
| Revenue by County | 43 | 2 |
| Branded vs. Generics | 45 | 1 |
| Treatment Algorithm | 46 | 1 |
| Annual Cost of Treatment | 47 | 1 |
| Treatment Usage Patterns | 48 | 1 |
| Disease Population | 49 | 1 |
| Treatment Seeking Population | 49 | 1 |
| Diagnosis Population | 49 | 1 |
| Prescription Population | 49 | 1 |
| Drivers and Barriers for Multiple Sclerosis Therapeutics Market | 49 | 1 |
| Drivers for Multiple Sclerosis Therapeutics Market | 49 | 1 |
| Barriers for Multiple Sclerosis Therapeutics Market | 50 | 1 |
| Psoriasis Therapeutics Market | 51 | 1 |
| Introduction | 51 | 1 |
| Revenue | 52 | 1 |
| Revenue by Country | 53 | 1 |
| Branded vs. Generics | 54 | 1 |
| Treatment Algorithm | 55 | 1 |
| Annual Cost of Treatment | 55 | 1 |
| Treatment Usage Pattern | 56 | 1 |
| Disease Population | 57 | 1 |
| Treatment Seeking Population | 57 | 1 |
| Diagnosis Population | 57 | 1 |
| Prescription Population | 57 | 1 |
| Drivers and Barriers for Psoriasis Therapeutics Market | 58 | 1 |
| Drivers for Psoriasis Therapeutics Market | 58 | 1 |
| Barriers for Psoriasis Therapeutics Market | 58 | 1 |
| Inflammatory Bowel Disease Therapeutics Market | 59 | 1 |
| Introduction | 59 | 1 |
| Revenue | 60 | 1 |
| Revenue by Country | 61 | 1 |
| Branded vs. Generics | 62 | 1 |
| Treatment Algorithm | 63 | 2 |
| Annual Cost of Treatment | 65 | 1 |
| Treatment Usage Pattern | 66 | 1 |
| Disease Population | 67 | 1 |
| Treatment Seeking Population | 67 | 1 |
| Diagnosis Population | 67 | 1 |
| Prescription Population | 67 | 1 |
| Drivers and Barriers for the Inflammatory Bowel Disease Therapeutics Market | 68 | 1 |
| Drivers for the Inflammatory Bowel Disease Therapeutics Market | 68 | 1 |
| Barriers for Inflammatory Bowel Disease Therapeutics Market | 69 | 1 |
| Systemic Lupus Erythematosus Therapeutics Market | 69 | 1 |
| Introduction | 69 | 1 |
| Revenue | 70 | 1 |
| Revenue by Country | 71 | 1 |
| Branded vs. Generics | 72 | 1 |
| Treatment Algorithm | 73 | 1 |
| Annual Cost of Treatment | 74 | 1 |
| Treatment Usage Pattern | 75 | 1 |
| Disease Population | 76 | 1 |
| Treatment Seeking Population | 76 | 1 |
| Diagnosis Population | 77 | 1 |
| Prescription Population | 77 | 1 |
| Drivers and Barriers for the Systemic Lupus Erythematosus Therapeutics Market | 78 | 1 |
| Drivers for the Systemic Lupus Erythematosus Therapeutics Market | 78 | 1 |
| Barriers for Systemic Lupus Erythematosus Therapeutics Market | 79 | 1 |
| Autoimmune Disorders Therapeutics Market to 2017: Pipeline Analysis | 80 | 58 |
| Introduction | 80 | 2 |
| Autoimmune Disorders Therapeutics Market Pipeline Assessment by Clinical Phase of Development | 82 | 1 |
| Filed Molecules | 82 | 3 |
| Phase III | 85 | 22 |
| Phase II | 107 | 8 |
| Phase I | 115 | 3 |
| Preclinical Phase | 118 | 8 |
| Discovery Phase | 126 | 2 |
| Profiles of Promising Molecules in the Autoimmune Disorders Therapeutics Market | 128 | 1 |
| ABT-874 | 128 | 1 |
| Introduction | 128 | 1 |
| Mechanism of Action | 128 | 1 |
| Clinical Trial Management | 128 | 1 |
| Actemra | 128 | 1 |
| Introduction | 128 | 1 |
| Mechanism of Action | 129 | 1 |
| Clinical Trial Management | 129 | 1 |
| Biferonex | 129 | 1 |
| Introduction | 129 | 1 |
| Mechanism of Action | 129 | 1 |
| Clinical Trial Management | 129 | 1 |
| Fampyra | 130 | 1 |
| Introduction | 130 | 1 |
| Mechanism of Action | 130 | 1 |
| Clinical Trial Management | 130 | 1 |
| Iguratimod | 130 | 1 |
| Introduction | 130 | 1 |
| Mechanism of Action | 131 | 1 |
| Clinical Trial Management | 131 | 1 |
| LAS41002 | 131 | 1 |
| Introduction | 131 | 1 |
| Mechanism of Action | 131 | 1 |
| Clinical Trial Management | 132 | 1 |
| MAbThera | 132 | 1 |
| Introduction | 132 | 1 |
| Mechanism of Action | 132 | 1 |
| Clinical Trial Management | 133 | 1 |
| Rebif | 133 | 1 |
| Introduction | 133 | 1 |
| Mechanism of Action | 133 | 1 |
| Clinical Trial Management | 134 | 1 |
| Remicade | 134 | 1 |
| Introduction | 134 | 1 |
| Mechanism of Action | 134 | 1 |
| Clinical Trial Management | 134 | 1 |
| Simponi | 135 | 1 |
| Introduction | 135 | 1 |
| Mechanism of Action | 135 | 1 |
| Clinical Trial Management | 135 | 1 |
| T-614 | 136 | 1 |
| Introduction | 136 | 1 |
| Mechanism of Action | 136 | 1 |
| Clinical Trial Management | 136 | 1 |
| Zushima | 137 | 1 |
| Introduction | 137 | 1 |
| Mechanism of Action | 137 | 1 |
| Clinical Trial Management | 137 | 1 |
| Autoimmune Disorders Therapeutics Market to 2017: Competitive Profiling | 138 | 10 |
| Market Share Analysis | 138 | 1 |
| Competitive Profiling | 138 | 1 |
| Abbott Laboratories | 138 | 1 |
| Company Overview | 138 | 1 |
| Marketed Products | 139 | 1 |
| SWOT Analysis | 139 | 1 |
| Pfizer Inc. | 139 | 1 |
| Company Overview | 139 | 1 |
| Marketed Products | 140 | 1 |
| SWOT Analysis | 140 | 1 |
| Johnson &Johnson | 141 | 1 |
| Company Overview | 141 | 1 |
| Marketed Products | 141 | 1 |
| SWOT Analysis | 141 | 1 |
| Biogen Idec Inc. | 142 | 1 |
| Company Overview | 142 | 1 |
| Marketed Products | 142 | 1 |
| SWOT Analysis | 143 | 1 |
| Amgen Inc. | 143 | 1 |
| Company Overview | 143 | 1 |
| Marketed Products | 143 | 1 |
| SWOT Analysis | 144 | 1 |
| Bayer AG | 145 | 1 |
| Company Overview | 145 | 1 |
| Marketed Products | 145 | 1 |
| SWOT Analysis | 145 | 1 |
| Sanofi | 146 | 1 |
| Company Overview | 146 | 1 |
| Marketed Products | 146 | 1 |
| SWOT Analysis | 147 | 1 |
| Autoimmune Disorders Therapeutics Market to 2017: Strategic Consolidations | 148 | 28 |
| Overview | 148 | 1 |
| Mergers and Acquisitions | 149 | 1 |
| Segmentation by Indication | 149 | 1 |
| Segmentation by Year | 150 | 1 |
| Segmentation by Deal Type | 151 | 1 |
| Segmentation by Deal Value | 152 | 2 |
| Segmentation by Geography | 154 | 1 |
| Co-development Deals | 155 | 1 |
| Segmentation by Indication | 155 | 1 |
| Segmentation by Year | 156 | 1 |
| Segmentation by Value | 157 | 1 |
| Segmentation by Geography | 158 | 3 |
| Summary of Co-development Deals | 161 | 1 |
| AstraZeneca Enters into Research and Development Agreement with Galderma Pharma | 161 | 1 |
| Elan Enters into Collaboration with Pharmaceutical Product Development | 161 | 1 |
| Lycera Enters into Research Agreement with Merck | 162 | 1 |
| Phosphagenics Enters into Co-Development Agreement with US-based Dermatology Company in 2011 | 162 | 1 |
| Proteostasis Therapeutics Enters into Co-Development Agreement with Elan | 162 | 1 |
| Licensing Deals | 163 | 1 |
| Segmentation by Indication | 163 | 1 |
| Segmentation by Year | 164 | 1 |
| Segmentation by Value | 165 | 1 |
| Segmentation by Geography | 166 | 7 |
| Summary of Licensing Deals | 173 | 1 |
| Xoma Enters into Licensing Agreement with Les Laboratoires Servier for Xoma 052 | 173 | 1 |
| Viropro Enters into Licensing Agreement with Spectrum Pharmaceuticals for Rituximab | 173 | 1 |
| Synta Pharmaceuticals Extends its Licensing Agreement with Roche | 173 | 1 |
| SuppreMol Enters into Licensing Agreement with Bayerische | 174 | 1 |
| MedImmune Enters into Licensing Agreement with Amgen for AMG 108 | 174 | 1 |
| Harbor BioSciences Enters into Licensing Agreement with China State Institute of Pharmaceutical Industry | 174 | 1 |
| Glenmark Pharmaceuticals Enters into Licensing Agreement with Sanofi for GBR500 | 175 | 1 |
| Circassia Enters into Licensing Agreement with Airmid for PAP-1 | 175 | 1 |
| Autoimmune Disorders Therapeutics Market to 2017: Appendix | 176 | 8 |
| Market Definitions | 176 | 1 |
| Abbreviations | 176 | 2 |
| Sources | 178 | 1 |
| Research Methodology | 178 | 2 |
| Coverage | 179 | 1 |
| Secondary Research | 179 | 1 |
| Primary Research | 179 | 1 |
| Therapeutic Landscape | 180 | 3 |
| Epidemiology-based Forecasting | 180 | 2 |
| Market Size by Geography | 182 | 1 |